Tripos Releases Version 7.2 of Its SYBYL Molecular Modeling Suite.

ST. LOUIS -- Release Features Enhanced Docking and Virtual Screening Products, Numerous User Improvements; Introduces Tripos' New Maintenance Release Program

Tripos, Inc. (Nasdaq:TRPS), a leading provider of drug discovery informatics products and chemistry research, today announced the release of SYBYL(R) 7.2, the latest version of the leading integrated molecular modeling environment for drug discovery research. Available immediately, SYBYL 7.2 includes many enhancements suggested by customers and reinforces Tripos' ongoing commitment to software quality, usability and innovative science.

The SYBYL 7.2 release features additional enhancements to Tripos' next-generation pharmacophore determination and molecular alignment tool, GALAHAD(TM), building on Tripos' investment in next-generation science to address the shortcomings of all current ligand-based design technologies. SYBYL 7.2 also includes a redesigned docking interface to improve users' workflows with full support of the FlexX Release 2.0 virtual screening suite.

"This latest release of SYBYL strengthens our offering for the molecular modeling user community and is a reaffirmation of Tripos' long-standing commitment to invest in scientific innovation," said Dr. David Lowis, senior director of product management at Tripos. "SYBYL 7.2 delivers enhancements in computational structure-based and ligand-based methods, enabling our customers to better design and efficiently advance active compounds in discovery projects."

Starting with the release of SYBYL 7.2, Tripos is launching a new maintenance release program to more rapidly provide updates and enhancements to products in the SYBYL suite. These updates will be available for download by customers at http://www.tripos.com more frequently than major SYBYL releases. The maintenance release program will allow improved response to the scientific and software needs of Tripos' global user community.

FlexX Release 2.0 lets the scientist combine the protein flexibility features of FlexE with either the pharmacophore constraints of FlexX-Pharm or the fast combinatorial library docking of FlexXC. FlexX Release 2.0 performance is up to 50 percent faster and shows improved accuracy over its well-validated predecessors. FlexX Release 2.0 can now be fully and easily accessed from the SYBYL 7.2 environment.

About Tripos, Inc.

Tripos (Nasdaq:TRPS) combines leading-edge technology and innovative science to deliver consistently superior chemistry-research products and services for the biotechnology, pharmaceutical and other life science industries. Within Tripos' Discovery Informatics (DI) business, the company provides software products and consulting services to develop, manage, analyze and share critical drug discovery information. Within Tripos' Discovery Research (DR) business, Tripos' medicinal chemists and research scientists partner directly with clients in their research initiatives, leveraging state-of-the-art information technologies and research facilities. Headquartered in St. Louis, Mo., Tripos spans the world with global research operations and an international client base. Further information on Tripos can be found at http://www.tripos.com.